MX2019000031A - Procedimientos para la preparación de una solución de levotiroxina. - Google Patents

Procedimientos para la preparación de una solución de levotiroxina.

Info

Publication number
MX2019000031A
MX2019000031A MX2019000031A MX2019000031A MX2019000031A MX 2019000031 A MX2019000031 A MX 2019000031A MX 2019000031 A MX2019000031 A MX 2019000031A MX 2019000031 A MX2019000031 A MX 2019000031A MX 2019000031 A MX2019000031 A MX 2019000031A
Authority
MX
Mexico
Prior art keywords
levothyroxine
preparation
solution
methods
water
Prior art date
Application number
MX2019000031A
Other languages
English (en)
Inventor
Psarrakis Yannis
Lioumis Kosta
Original Assignee
Emp Pharmaceuticals B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emp Pharmaceuticals B V filed Critical Emp Pharmaceuticals B V
Publication of MX2019000031A publication Critical patent/MX2019000031A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un procedimiento para la preparación de una composición de levotiroxina oral, que comprende las etapas de combinar levotiroxina o una sal de la misma, un disolvente orgánico miscible con agua o un alcohol de azúcar y agua, ajustar el pH a al menos 8 proporcionando un medio acuoso básico, disolver la levotiroxina en el medio acuoso básico para obtener una solución de levotiroxina y disminuir el pH de la solución de levotiroxina a entre 3,5-4,9. También se describe una composición de levotiroxina oral obtenible mediante dicho procedimiento y su uso como medicamento.
MX2019000031A 2016-07-05 2017-07-05 Procedimientos para la preparación de una solución de levotiroxina. MX2019000031A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662358270P 2016-07-05 2016-07-05
NL2017110A NL2017110B1 (en) 2016-07-05 2016-07-05 Methods for the preparation of a levothyroxine solution
PCT/EP2017/066823 WO2018007466A1 (en) 2016-07-05 2017-07-05 Methods for the preparation of a levothyroxine solution

Publications (1)

Publication Number Publication Date
MX2019000031A true MX2019000031A (es) 2019-08-01

Family

ID=56936493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000031A MX2019000031A (es) 2016-07-05 2017-07-05 Procedimientos para la preparación de una solución de levotiroxina.

Country Status (7)

Country Link
US (2) US11096915B2 (es)
EP (1) EP3481426A1 (es)
JP (1) JP6664804B2 (es)
CA (1) CA3029569C (es)
MX (1) MX2019000031A (es)
NL (1) NL2017110B1 (es)
WO (1) WO2018007466A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2017110B1 (en) * 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution
CN117085022A (zh) * 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂
EP4061331A1 (en) 2019-11-22 2022-09-28 Wockhardt Limited Oral film composition comprising levothyroxine
CN116421557A (zh) * 2023-06-02 2023-07-14 泊诺(天津)创新医药研究有限公司 一种左甲状腺素钠口服液的制备方法
CN117919171B (zh) * 2024-03-22 2024-05-31 泊诺(天津)创新医药研究有限公司 一种左甲状腺素钠口服液的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1011118B (zh) 1986-06-13 1991-01-09 天津医学院附属医院 治疗白内障的眼药水的制药方法
GB9420705D0 (en) 1994-10-14 1994-11-30 Boots Co Plc Process
ATE271863T1 (de) * 1995-11-14 2004-08-15 Abbott Gmbh & Co Kg Schilddrüsenhormone enthaltende stabilisierte arzneimittel und verfahren
IT1302201B1 (it) 1998-09-11 2000-07-31 Bracco Spa Processo per la produzione di ormoni tiroidei.
US20030199588A1 (en) * 2001-02-15 2003-10-23 Franz G. Andrew Levothyroxine compositions and methods
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
JP2003255338A (ja) 2002-02-28 2003-09-10 Mitsubishi Electric Corp 液晶表示装置
JP5173832B2 (ja) 2006-01-06 2013-04-03 インターベツト・インターナシヨナル・ベー・ベー 濃縮液体甲状腺ホルモン組成物
US9345722B2 (en) 2006-07-24 2016-05-24 Emisphere Technologies, Inc. Pharmaceutical formulations for the treatment of alzheimer's disease
EP2274167A1 (en) 2008-05-06 2011-01-19 Lenzi Egisto S.p.A. Protective textile material against the action of melted materials
WO2009136249A1 (en) * 2008-05-09 2009-11-12 Cadila Pharmaceuticals Ltd. An improved process for the preparation of levothyroxine sodium with reduced levels of impurities
WO2012120338A1 (en) * 2011-03-10 2012-09-13 Emp Pharma Gmbh Method for the preparaton of a levothyroxine solution
GR1008017B (el) * 2012-08-03 2013-10-24 Verisfield (Uk) Ltd, Υποκαταστημα Ελλαδας, Εμπορια Φαρμακων, Σταθερο φαρμακευτικο συστημα (κιτ) για την παρασκευη ποσιμου διαλυματος λεβοθυροξινης ή φαρμακευτικως αποδεκτου αλατος αυτης
US8779000B1 (en) * 2013-07-20 2014-07-15 Nilesh Parikh Saccharide free, storage stable thyroid hormone active drug formulations and methods for their production
RU2673540C2 (ru) * 2014-03-31 2018-11-28 Люпин Лимитед Способ получения левотироксина и его солей
US9345772B1 (en) * 2015-02-27 2016-05-24 Nilesh Parikh Liquid levothyroxine formulations
NL2017110B1 (en) * 2016-07-05 2018-01-12 Emp Levo Gmbh Methods for the preparation of a levothyroxine solution

Also Published As

Publication number Publication date
US20210353577A1 (en) 2021-11-18
JP2019521185A (ja) 2019-07-25
CA3029569A1 (en) 2018-01-11
US20190321316A1 (en) 2019-10-24
JP6664804B2 (ja) 2020-03-13
US11096915B2 (en) 2021-08-24
CA3029569C (en) 2020-08-11
EP3481426A1 (en) 2019-05-15
NL2017110B1 (en) 2018-01-12
US11938109B2 (en) 2024-03-26
WO2018007466A1 (en) 2018-01-11

Similar Documents

Publication Publication Date Title
MX2019000031A (es) Procedimientos para la preparación de una solución de levotiroxina.
WO2017070616A3 (en) Sexually transmitted disease vaccines
WO2017100726A8 (en) Methods for treating huntington's disease
PH12017500048A1 (en) Pyridone derivative having tetrahydropyranylmethyl group
WO2013100176A3 (en) Method of producing a low odor glycerin derivative-modified silicone or a composition comprising the same
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
EP4327880A3 (en) Solid state form of ribociclib succinate
EA202091271A2 (ru) Гемисульфатная соль 5,10-метилен-(6r)-тетрагидрофолиевой кислоты
PH12016501175A1 (en) Formulations of deoxycholic acid and salts thereof
AU2016237099B2 (en) Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same
NZ711343A (en) Sodium salt of (2s, 5r)-6-benzyloxy-7-oxo-1,6-diaza-bicyclo [3.2.1 ] octane-2-carboxylic acid and its preparation
CA2899024C (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
AR074545A1 (es) Proceso de preparacion de dihidroetorfina
WO2017015433A3 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
PH12016500913A1 (en) Soap bar
WO2016015066A8 (de) Verfahren zum herstellen einer flüssigen pharmazeutischen zubereitung
BR112018013408A2 (pt) derivados de c-glicosídeo que têm anel fenila fusionado ou sais farmaceuticamente aceitáveis dos mesmos, método para preparar os mesmos e composição farmacêutica compreendendo os mesmos
MX2019001691A (es) Composiciones que comprenden biopolímeros y métodos para su elaboración.
MX2018005028A (es) Composicion para el cuidado de la piel y metodos para la misma.
EP3987931A4 (en) AQUEOUS SOLUTION COMPRISING AN INCLUSION COMPLEX, METHOD FOR OBTAINING IT AND ITS USE FOR APPLICATION IN CROPS AND IMPROVING THEIR YIELD
WO2012015255A3 (en) Novel montelukast 4-halobenzylamine salt and method for preparing montelukast sodium salt by using the same
WO2016022700A8 (en) Tlr-independent small molecule adjuvants
PH12014502844B1 (en) Method for producing concentrated aqueous solution of organic compound